Second solid cancers after radiotherapy for breast cancer in SEER cancer registries by Berrington de Gonzalez, A et al.
Second solid cancers after radiotherapy for breast cancer in
SEER cancer registries
A Berrington de Gonzalez*,1, RE Curtis
1, E Gilbert
1, CD Berg
2, SA Smith
3, M Stovall
3 and E Ron
1
1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20814, USA;
2Early Detection
Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20814, USA;
3Department of Radiation Physics, University of
Texas M.D. Anderson Cancer Center, Houston, TX 70330, USA
BACKGROUND: Radiotherapy for breast cancer reduces disease recurrence and breast cancer mortality. However, it has also been
associated with increased second cancer risks in exposed sites.
METHODS: We evaluated long-term second cancer risks among 182057 5-year survivors of locoregional invasive breast cancer
diagnosed between 1973 and 2000 and reported to US NCI-SEER Program cancer registries. Multivariate Poisson regression
was used to estimate the relative risk (RR) and excess cases of second cancer in women who had surgery and radiotherapy,
compared with those who had surgery alone. Second cancer sites were grouped according to doses received from typical tangential
breast fields.
RESULTS: By the end of 2005 (median follow-up¼13.0 years), 15498 second solid cancers had occurred, including 6491 contralateral
breast cancers. The RRs for radiotherapy were 1.45 (95% confidence interval (CI)¼1.33–1.58) for high-dose second cancer
sites (1þ Gy: lung, oesophagus, pleura, bone and soft tissue) and 1.09 (1.04–1.15) for contralateral breast cancer (E1Gy).
These risks decreased with increasing age and year of treatment. There was no evidence of elevated risks for sites receiving medium
(0.5–0.99Gy, RR¼0.89 (0.74–1.06)) or low doses (o0.5Gy, RR¼1.01 (0.95–1.07)). The estimated excess cases of cancer in
women treated with radiotherapy were as follows: 176 (95% CI¼69–284) contralateral breast cancers or 5% (2–8%) of the total in
all 1þyear survivors, and 292 (222–362) other solid cancers or 6% (4–7%) of the total.
CONCLUSIONS: Most second solid cancers in breast cancer survivors are not related to radiotherapy.
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Substantial improvements in breast cancer treatment and screen-
ing signify that nearly 90% of women diagnosed with breast cancer
survive for 45 years (Berry et al, 2005; Ries et al, 2008). Currently,
an estimated 2.5 million breast cancer survivors live in the United
States (Ries et al, 2008), and the long-term health of these women
is an important public health issue. A recent descriptive analysis
of Surveillance Epidemiology and End Results Program (SEER)
cancer registries found that breast cancer survivors have an 18%
higher risk of developing a subsequent cancer compared with the
general population (Curtis et al, 2006). Shared environmental and
genetic factors are likely to be involved, but some of the increased
risk is probably a late adverse effect from the cancer treatments
such as radiotherapy (Clarke et al, 2005). Randomised trials and
cancer registry-based studies have shown that radiotherapy
significantly reduces the risk of recurrence and breast cancer
mortality, and also increases the risk of second cancers of the lung,
oesophagus, soft tissue, contralateral breast and leukaemia (Huang
and Mackillop, 2001; Gao et al, 2003; Zablotska and Neugut, 2003;
Clarke et al, 2005; Zablotska et al, 2005).
Surveillance Epidemiology and End Results Program registries
cover the largest population of any national cancer registries and
contain information on radiotherapy treatment, tumour character-
istics and have long-term follow-up. In this study, we performed
the first systematic evaluation of all second solid cancer risks after
radiotherapy treatment for invasive breast cancer in the United
States using the SEER databases. The large sample size and long-
term follow-up enabled evaluation of patterns of effect modifica-
tion, estimation of the number of excess cases and the proportion
of second solid cancers occurring among breast cancer survivors
that might be attributable to radiotherapy.
MATERIALS AND METHODS
Population and follow-up
The cohort was composed of women who were diagnosed with
a first primary invasive locoregional breast cancer reported to one
of the nine SEER registries between 1 January 1973 and 31
December 2000 (n¼328691). As there is at least a 5-year lag
period between radiation exposure and solid cancer induction
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for 5 years. The follow-up time for second cancers began 5 years
after the date of initial cancer diagnosis and ended at the date of
diagnosis of second primary cancer, at last known vital status,
death or at the end of the study (31 December 2005), whichever
occurred first. As underreporting of second cancers has been noted
to occur among elderly patients who frequently have other
comorbid conditions (Fraumeni et al, 2006), we excluded women
whose first breast cancer was diagnosed after the age of 75 years
(n¼33214) and restricted follow-up to attained ages o80 years.
We also excluded women if it was unknown whether they had
received radiotherapy (n¼352), chemotherapy (n¼1273) or
hormonal therapy (n¼1304); women who did not have breast
cancer surgery or if surgery was unknown (n¼4848) and women
who had distant metastases at diagnosis or unknown disease stage
(n¼7853). As a number of women were missing more than one
piece of information, the final cohort included 182057 women.
Treatment information
Women were classified according to whether they had received
radiotherapy as part of their initial breast cancer treatment.
Surgery was classified as mastectomy (total, modified radical,
extended radical mastectomy) or breast-conserving surgery
(partial mastectomy, lumpectomy, wedge resection, quadrantect-
omy, segmental mastectomy, tylectomy, subcutaneous mastect-
omy). Before 1983, the type of surgery performed was not available
in SEER, but as breast-conserving surgery was rare, surgery before
this date was assumed to have been mastectomy. The effects of
chemotherapy and hormonal therapy were not assessed directly
because of concerns regarding underascertainment in SEER
(Brown et al, 2000), but the relative risks (RRs) for radiotherapy
were adjusted for chemotherapy and hormonal therapy treatment.
We grouped second cancer sites a priori into three dose groups
according to the estimated mean organ dose from the basic breast
cancer radiotherapy treatment involving tangential fields: high
(1þ Gy), medium (0.5–0.99Gy) and low (o0.5Gy) dose. This
dosimetry was conducted using thermoluminscent dosimeters in
tissue equivalent phantoms assuming a standard treatment protocol
with 50Gy tumour dose and beam energy of 6MV photons
(Appendix A) (Stovall et al, 2006; Stovall et al, 2008). Ipsilateral
second breast cancers were excluded because of the difficulty in
distinguishing between recurrence and subsequent primary cancer.
Statistical analysis
The observed (O) number of second cancers for each site was
compared with the expected (E) number in women in the general
population. The expected number of second cancers was estimated
by multiplying age-, sex-, race- and calendar-period-specific
cancer incidence rates in the nine SEER registries by stratum-
specific person-years at risk and then summing across strata
(Seer*stat, version 6.4.4). Standardised incidence ratios (SIRs)
were calculated by dividing the observed number of cancers (O) by
the expected number (E). Tests of statistical significance were two
sided and were based on Poisson exact methods (Liddell, 1984).
Multivariate Poisson regression analysis (using Epicure, 2007) was
used to estimate the RR (and 95% confidence intervals (CI)) for the
groups of second solid cancers (defined above according
to dose) after radiotherapy and surgery compared with surgery
alone, with the expected number of second cancers used as an offset.
If Or and Er indicate the number of observed and expected cancers,
respectively, in the surgeryþradiotherapy (r¼1) and surgery alone
(r¼0) groups, then the statistical expectation of Or is given by
Or ¼ yEr½1 þ br 
where y and b are parameters to be estimated and 1þb is the RR
associated with radiotherapy. The use of the expected number of
cancers as an offset indirectly adjusts for potential confounding
by attained age and attained calendar period (Yasui et al, 2003).
Analyses were additionally adjusted for breast cancer stage,
age at and year of breast cancer diagnosis, chemotherapy
and hormonal therapy treatment (yes/no) through stratification.
Trend tests were conducted using ordinal categories as continuous
variables.
We investigated potential effect modifiers by stratification,
including age at, year of and time since first cancer diagnosis, as
well as stage and type of surgery (breast-conserving vs mastect-
omy). As the majority of women who receive breast-conserving
surgery are recommended to receive radiotherapy, the proportion
of women who had this type of surgery without radiotherapy in
SEER was relatively small (17%), and this subgroup is unlikely to
be a representative subset of breast cancer patients. Therefore,
to obtain stable risk estimates in subgroup analyses according to
surgery type, we used a combined surgery-only comparison group
that included both breast-conserving surgery and mastectomy
patients. Tests for heterogeneity between surgery types took
account of the lack of independence of the comparison group
(Berrington and Cox, 2003).
The number of excess cancers related to radiotherapy was
estimated as the number of cases in those treated with radio-
therapy minus the estimated number of cases that would have
occurred in these women if they had not received radiotherapy.
The proportion of second cancers attributable to radiotherapy was
estimated by dividing this excess by the total number of second
cancers in both 1þ and 5þ year survivors. Although it is unlikely
that there are any radiation-related cancers before 5 years, the
attributable risk among all survivors (defined here as 1þ years) is
the most relevant summary statistic for all breast cancer survivors.
The excess absolute risk (per 10000 person-years) was estimated
by dividing the excess by the associated number of person-years.
RESULTS
Overall, 38% of women with breast cancer had surgeryþ
radiotherapy and 62% were treated with surgery alone (Table 1).
Radiotherapy was slightly less common in those who were older
at diagnosis, was increasingly common over time and was
more frequent in those who received breast-conserving surgery.
Within categories of surgery type, stage was related to treat-
ment with radiotherapy, particularly after mastectomy, in which
radiotherapy was more common after regional than after localised
disease (27 vs 8%).
The women were followed up for an average of 13 years. During
the follow-up period (1978–2005), a total of 15498 women
developed a second primary solid cancer, including 6491
contralateral breast cancers (Table 2). Women treated with
surgeryþradiotherapy had a higher risk of several second solid
cancers compared with the general female population, with more
than two-fold SIRs observed for oesophageal, pleural, bone, soft
tissue and contralateral breast cancer. These sites typically receive
doses from radiotherapy of 1Gy or more (Appendix A). The
adjusted RRs for surgeryþradiotherapy, compared with surgery
alone, were 1.09 (1.04–1.15) for contralateral breast cancer, 1.45
(95% CI¼1.33–1.58) for high-dose, 0.89 (0.74–1.06) for medium-
dose and 1.01 (0.95–1.07) for low-dose sites.
For sites in the high-dose group, the RR for surgeryþradiother-
apy, compared with surgery alone, decreased with increasing age at
treatment (P-trendo0.001) and with increasing year of treatment
(P-trend¼0.01), but increased with increasing time since diag-
nosis (P-trendo0.001) (Table 3). For patients diagnosed with
breast cancer in 1983 or later, the risks were higher after
mastectomy (RR¼1.50, 95% CI¼1.22–1.82) than after breast-
conserving surgery (RR¼1.28, 95% CI¼1.14–1.43), but the
difference was not statistically significant (P40.5).
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dose group that had the largest number of cases: lung, oesophagus
and soft tissue. The RR of lung cancer was significantly increased
(RR¼1.38 (95% CI¼1.26–1.51)) and was higher for ipsilateral
than for contralateral lung cancer (1.54 (1.36–1.75) vs 1.18 (1.02–
1.35)). For patients diagnosed with breast cancer in 1983 or later,
lung cancer risk was higher after mastectomy (RR¼1.43 (95%
CI¼1.15–1.77)) than after breast-conserving surgery, but was still
significantly elevated (RR¼1.20 (1.07–1.36)). For oesophageal
cancers, the RR was 1.99 (1.37–2.88), and there was no differ-
ence according to surgery type. Overall, the risk for soft tissue
cancers was 2.52 (1.67–3.81), but it was especially highly elevated
for angiosarcomas (RR¼13.7 (4.0–95.6)). The majority of angio-
sarcomas diagnosed in women who had surgeryþradiotherapy
were located in the thorax (n¼12 out of 16).
The RR for contralateral breast cancer in women who had
surgeryþradiotherapy, compared with those who had surgery
alone, decreased with increasing age at first breast cancer
treatment (P-trend¼0.03, Table 4). The RR was lower for cancers
treated after 1993 (P-trend¼0.02), but was not clearly associated
with time since treatment, stage or type of surgery.
In total, there were an estimated 176 (95% CI¼69–284) excess
cases of contralateral breast cancer in women who had surgeryþ
radiotherapy, or 5% (95%CI¼2–7%) of the contralateral breast
cancers diagnosed in 1 year survivors (Table 5). The excess
absolute risk of contralateral breast cancer associated with
radiotherapy was 2 (1–4) cases per 10000 person-years. There
were an estimated 292 (95% CI¼222–362) excess cases of solid
cancers (other than contralateral breast cancer) in women who had
radiotherapy, or 6% (3–8%) of the total in 1 year survivors
(Table 5). The excess was largely composed of cancers of the lung
(B80%). The excess absolute risk for these cancers associated
with radiotherapy was 4 (3–5) cases per 10000 person-years.
When considering only 5þyear survivors, the attributable risk
estimates were slightly higher: 8% (3–14%) for contralateral breast
cancer and 10% (5–14%) for other solid cancers.
DISCUSSION
In this large long-term study of breast cancer survivors,
significantly increased RRs of second solid cancers after radio-
therapy were observed for the group of sites that typically receive
the highest radiation exposure (X1Gy). There was no overall
excess risk for the group of sites that typically receive lower
radiation exposures (o1Gy). In total, it was estimated that
about 5% (95% CI¼2–7%) of contralateral breast cancers and
6% (3–8%) of other solid cancers occurring among 1þyear
survivors could be related to radiotherapy. Risks were generally
lower for more recent treatment periods and higher for younger
ages at treatment.
To our knowledge, this is the first study to assess and quantify
the long-term risk of all solid cancers after breast cancer
radiotherapy in the United States. Our site-specific results were
broadly similar to those from a pooled analysis of 63 randomised
clinical trials of breast cancer radiotherapy (Clarke et al, 2005) and
several observational studies. In these studies, there was evidence
of increased risks of lung (Zablotska and Neugut, 2003;
Roychoudhuri et al, 2004; Clarke et al, 2005; Darby et al, 2005;
Andersson et al, 2008; Schaapveld et al, 2008), oesophageal
(Zablotska and Neugut, 2003; Roychoudhuri et al, 2004; Clarke
et al, 2005) and contralateral breast cancer (Gao et al, 2003;
Roychoudhuri et al, 2004; Clarke et al, 2005), as well as soft tissue
sarcomas (Huang and Mackillop, 2001; Clarke et al, 2005;
Andersson et al, 2008), in women treated with radiotherapy
compared with unirradiated women. In the pooled analysis of
clinical trials (Clarke et al, 2005), the authors did not estimate
attributable risks, but it was possible to estimate them on the basis
of the data presented. Overall, about 8% of total cancers were
attributable to radiotherapy, slightly higher than the estimate from
this study.
Our results suggested that, in general, radiation-related risks
were lower among women treated in more recent years (1993þ).
This is likely the result of several factors, including reduced
volume of irradiated tissues such as the lung, since the
introduction of computed tomography planning (Muren et al,
2002; Wang and Harris, 2004; Van der Laan et al, 2008), and also
because of shorter available follow-up time. Another factor that
probably contributed to this trend was the increasing use of
breast-conserving surgery. Although detailed treatment informa-
tion was not available in SEER, women who received mastectomy
probably received supraclavicular, and possibly also internal
mammary irradiation, more often than women who had breast-
conserving surgery, which would increase doses (Appendix A).
In an earlier analysis of lung cancer risk after breast cancer
radiotherapy in the SEER registries, it was suggested that there was
no increased risk of lung cancer in women who had breast-
conserving surgery (Zablotska et al, 2005). We used a combined
comparison group of women who had surgery only (mastectomy
or breast-conserving surgery) in the current analysis to obtain a
broader, more representative referent group of women not treated
with radiotherapy. Using this approach, there was evidence of a
small, but significantly increased, risk of lung cancer and other
cancers in high-dose regions after breast-conserving surgery.
In terms of absolute numbers and fatality, lung cancer is by far
the most important second cancer after breast cancer, hence it
remains important to continue to monitor lung cancer risks after
current radiation treatment protocols, taking into account
smoking history (Prochazka et al, 2005; Kaufman et al, 2008).
Three earlier studies with individual dosimetry have reported
an increased risk of contralateral breast cancer after radiotherapy
in the youngest patients (oage 45) (Boice et al, 1992; Hooning
et al, 2008; Stovall et al, 2008). This is consistent with the well-
established modifying effects of age at radiation exposure; risk
decreases with increasing age at exposure and is particularly low
in post-menopausal women (Preston et al, 2002). This study and
Table 1 Descriptive statistics of the women who were diagnosed with a
primary invasive locoregional breast cancer diagnosed before age 75 who
survived 5 years (SEER 9 registries: 1973–2005)
Surgeryþ
radiotherapy
a Surgery only
a Total
Characteristic n % n % n %
All women 69296 38 112761 62 182057 100
Age at treatment (diagnosis)
o40 6104 39 9511 61 15615 100
40–49 17075 41 24711 59 41786 100
50–59 20056 40 30047 60 50103 100
60–69 18534 36 33460 64 51994 100
70–74 7527 33 15032 67 22559 100
Year of treatment (diagnosis)
1973–1982 8958 21 34681 79 43639 100
1983–1992 21366 32 46306 68 67672 100
1993 38972 55 31774 45 70746 100
Stage (breast conserving surgery)
Localised 39822 84 7503 16 47325 100
Regional 10456 81 2504 19 12960 100
Stage (mastectomy)
Localised 6216 8 67834 92 74050 100
Regional 12802 27 34920 73 47722 100
aOn the basis of initial treatment, chemotherapy and hormonal therapy were not
considered in this classification. Associations with radiotherapy Po0.001 for all
variables listed above (calculated using multivariable logistic regression).
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trials; Gao et al, 2003; Clarke et al, 2005) found an elevated
risk of contralateral breast cancer after radiotherapy following
young age at exposure, and also among post-menopausal women.
Given the large number of post-menopausal breast cancer patients
treated with radiotherapy, this is another question that warrants
further study. Although we found no difference in contralateral
breast cancer risk in women who had radiotherapy after
mastectomy compared with those who underwent breast-conserving
surgery, a recent Dutch study reported lower risks after
mastectomy (Hooning et al, 2008). However, the majority of
women in the Dutch study who had mastectomy were treated with
electrons rather than with photons, which should result in a lower
radiation dose to the contralateral breast (Stovall et al, 2008) and is
the most likely explanation for the difference in findings.
There are several limitations in the use of SEER cancer registries
to evaluate treatment-related second cancer risks. One limitation is
the potential for loss to follow-up if a patient moves from the
registry area, which would result in an underestimation of the
absolute number of second cancers and hence the excess absolute
risk estimates. However, mortality data are complete and
comparisons of our results for lung cancer incidence with an
earlier study of these women evaluating lung cancer mortality
produced similar results, suggesting that this bias is likely to be
small (Darby et al, 2005). Furthermore, the estimated attributable
fraction should be valid, unless loss to follow-up is greater in
one treatment group than in the other. Radiotherapy may
be underreported in SEER because only information pertaining
to the initial treatment course is collected (Malin et al, 2002).
Since type of surgery was only recorded in SEER after 1983, we
assumed that all breast cancer surgery before that time was
mastectomy. This assumption undoubtedly resulted in mis-
classification, which most likely reduced the RR in the mastectomy
group. Lack of individual data on actual treatment fields used
also meant that we had to use general dose groupings based on
typical organ doses from basic treatment fields. Even though
individual organ doses would vary if additional fields were used,
we think that it is unlikely that the rank order of organs, and hence
our dose groupings, would change significantly. This can
be observed in Appendix A for the use of tangential
fieldsþsupraclavicular fields.
As radiation treatment was not randomised, selection bias could
result in differences between treatment groups with regard to
smoking status and other variables that affect second cancer risk.
Information on other potential confounding factors such as
smoking is usually not available in cancer registry studies. The
patterns of risk we observed were consistent with the general
literature on radiation carcinogenesis, in that risks were higher for
sites that should have received higher doses and also higher for
younger ages at exposure (Preston et al, 2007). Furthermore, our
Table 2 Risk of second solid primary cancer after invasive locoregional breast cancer in 5-year survivors (SEER 9 registries: 1973–2005)
Surgeryþradiotherapy Surgery only
Observed Expected Observed Expected
Dose grouping
a Cancer site cases cases SIR cases cases SIR RR
b (95% CI)
High (1þ Gy) Oesophagus 56 24.98 2.24* 68 61.58 1.10
Pleura 2 0.22 9.14* 0 0.50 0
Lung 814 673.16 1.21* 1,387 1582.33 0.88*
Bone 13 4.14 3.14* 17 9.33 1.82*
Soft tissue
c 56 18.95 2.96* 48 42.50 1.13
Sub-total 941 721.50 1.30* 1520 1697.63 0.90* 1.45 (1.33–1.58)
Medium (0.5–0.99Gy) Stomach 56 54.18 1.02 158 138.36 1.14
Liver/gall bladder 35 61.90 0.57* 110 147.33 0.75*
Larynx 10 19.35 0.52* 35 47.27 0.74
Thyroid 72 62.78 1.15 129 122.43 1.05
CNS 4 2.76 1.45 8 6.13 1.31
Sub-total 177 200.98 0.88 440 461.75 0.95 0.89 (0.74–1.06)
Low (o0.5Gy) Oral cavity 61 64.74 0.94 147 158.72 0.93
Salivary gland 16 8.85 1.81* 24 20.26 1.18
Colon 364 387.89 0.94 921 975.15 0.94
Rectum 118 128.31 0.92 285 320.40 0.89
Pancreas 103 115.47 0.89 268 281.74 0.95
Melanoma of the skin 125 118.12 1.06 249 248.37 1.00
Cervix uteri 30 52.46 0.57* 75 124.08 0.60*
Ovary 219 152.42 1.43* 462 362.68 1.27*
Endometrial 421 301.52 1.40* 878 705.96 1.24*
Other female genital 33 37.45 0.88 80 88.47 0.90
Bladder 125 113.19 1.10 287 273.89 1.05
Kidney 71 85.30 0.83 170 191.37 0.89
Renal/other urinary tract 9 14.51 0.62 33 36.66 0.90
Brain 45 44.92 1.00 78 107.10 0.73*
Other sites 71 74.34 0.96 161 168.79 0.95
Sub-total 1811 1699.50 1.07* 4118 4063.64 1.01 1.01 (0.95–1.07)
All solid cancers (excluding
contralateral breast)
2929 2621.98 1.12* 6078 6223.02 0.98 1.11 (1.06–1.16)
Contralateral breast 2076 688.07 3.02* 4415 1571.94 2.81* 1.09 (1.04–1.15)
Abbreviations: CI¼confidence interval; CNS¼central nervous system; SIR¼standardised incidence ratio¼ratio of observed to expected cases.
aMean doses on the basis of
tangential fields breast radiotherapy, see Table 1. *Po0.05.
bRR¼relative risk calculated using Poisson regression stratified by stage, age at treatment, year of treatment,
chemotherapy and hormonal therapy.
cSoft tissue histology: surgeryþradiotherapy includes 16 angiosarcomas, 22 fibrosarcomas, 18 others and surgery only includes
2 angiosarcomas, 18 fibrosarcomas and 28 others.
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locoregional breast cancer in 5-year survivors (SEER 9 registries: 1973–2005)
Surgeryþradiotherapy Surgery only
Characteristic Observed Expected SIR Observed Expected SIR RR
a (95% CI)
P-trend/
homogeneity
Age at diagnosis
o40 45 17.33 2.60 50 47.07 1.06 2.67 (1.75–4.07)
40–49 195 119.86 1.63 310 318.74 0.97 1.67 (1.38–2.02)
50–59 310 251.87 1.23 542 625.41 0.87 1.40 (1.21–1.62)
60þ 391 332.45 1.18 618 706.41 0.87 1.31 (1.15–1.50) o0.001
Year of diagnosis
1973–1982 268 168.17 1.59 646 735.03 0.88 1.77 (1.52–2.05)
1983–1992 415 336.02 1.24 672 763.30 0.88 1.40 (1.24–1.59)
1993þ 258 217.30 1.19 202 199.30 1.01 1.15 (0.95–1.38) 0.01
Latency
5–9years 488 406.05 1.20 685 750.51 0.91 1.30 (1.15–1.47)
10–14years 268 190.88 1.40 455 485.07 0.94 1.51 (1.30–1.77)
15þ years 185 124.57 1.49 380 462.05 0.82 1.80 (1.50–2.16) o0.001
Disease stage
Localised 594 484.66 1.23 1051 1187.53 0.89 1.40 (1.25–1.55)
Regional 347 236.85 1.47 469 510.01 0.92 1.55 (1.35–1.80) 0.24
Surgery (1980þ)
b
Breast conserving 550 467.39 1.18 874 962.6 0.91 1.28 (1.14–1.43)
Mastectomy 123 85.94 1.43 1.50 (1.22–1.82) 40.5
c
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio¼ratio of observed to expected cancers.
aRR¼relative risk calculated using Poisson regression with
stratification by stage, age at treatment, year of treatment, chemotherapy and hormonal therapy.
bComparison group of surgery only was on the basis of breast conserving
surgery and mastectomy combined.
cEstimated using methods that account for shared comparison group (Berrington and Cox, 2003).
Table 4 Risk of contralateral breast cancer after invasive locoregional breast cancer in 5-year survivors (SEER 9 1973–2005)
Surgeryþradiotherapy Surgery only
Characteristic Observed Expected SIR Observed Expected SIR RR
a (95% CI)
P-trend/
homogeneity
Age at diagnosis
o40 277 41.05 6.75 490 97.15 5.04 1.30 (1.11–1.50)
40–49 517 166.07 3.11 1089 377.01 2.89 1.08 (0.97–1.20)
50–59 598 233.21 2.56 1437 542.25 2.65 0.98 (0.89–1.08)
60þ 684 247.74 2.76 1399 555.53 2.52 1.14 (1.04–1.26) 0.03
Year of diagnosis
1975–1982 557 160.34 3.47 2083 685.68 3.04 1.12 (1.02–1.23)
1983–1992 964 318.28 3.03 1849 699.15 2.64 1.14 (1.05–1.23)
1993þ 555 209.46 2.65 483 187.11 2.58 1.04 (0.92–1.18) 0.02
Latency
5–9years 1233 401.61 3.07 2194 736.14 2.98 1.06 (0.99–1.14)
10–14years 554 179.78 3.08 1236 450.07 2.75 1.12 (1.01–1.24)
15þ years 289 106.68 2.71 985 385.73 2.55 1.04 (0.91–1.19) 0.1
Disease stage
Localised 1337 454.98 2.94 2988 1088.40 2.75 1.10 (1.03–1.18)
Regional 739 233.09 3.17 1427 483.54 2.95 1.08 (0.98–1.18) 40.5
Surgery type (1980þ)
b
Breast conserving 1256 442.25 2.84 2332 886.26 2.63 1.10 (1.03–1.18)
Mastectomy 263 85.49 3.08 1.11 (0.97–1.26) 40.5
c
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio¼ratio of observed to expected cancers.
aRR¼relative risk calculated for treatment with
surgeryþradiotherapy compared with surgery alone using Poisson regression with stratification by stage, age at treatment, year of treatment, chemotherapy and hormonal
therapy. Women with bilateral breast cancer at diagnosis or unknown laterality were excluded.
bComparison group of surgery only was on the basis of breast conserving surgery
and mastectomy combined.
cCalculated using methods to account for the shared comparison group (Berrington and Cox, 2003).
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(Deutsch et al, 2003; Clarke et al, 2005), suggesting that any
residual confounding is unlikely to have been substantial. If
anything, residual confounding by smoking may have resulted in
an underestimation of risks if smokers were less likely to receive
radiotherapy than non-smokers.
The strengths of this study include the large size of the population-
based cohort and long-term follow-up, which enabled the evaluation
of relatively small RRs. We also conducted multivariate analyses to
ensure that we controlled for the available confounding factors,
including other breast cancer treatments and stage. This, plus the
assessment of all second solid cancer sites in a single study, enabled
the examination of effect modification by age and year of diagnosis,
as well as estimation of the excess number and attributable propor-
tion of second cancers that could be related to radiotherapy.
Most of the women in this study were treated in the past
(o1990), and breast cancer treatment and radiotherapy techni-
ques have changed considerably over the past three decades (Shank
et al, 2000; Taylor et al, 2007). Indeed, our estimates of RRs were
lower in those treated in more recent calendar years, and thus the
combined results may overestimate risks for current treatment.
Overall, 5–6% of second solid cancers in irradiated women were
estimated to be attributable to radiotherapy exposure. Among all
breast cancer survivors, this figure was 3%. Our findings suggest
that most second solid cancers after treatment for breast cancer are
related to other risk factors such as lifestyle or genetic factors.
When women and their physicians make treatment decisions, the
risk of radiotherapy-related cancer needs to be placed in
perspective and balanced with the known tumour control and
mortality benefits achieved from treatment.
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Appendix A
Table A1 Estimated typical organ doses from breast radiotherapy assuming 50Gy tumour dose and 6MV photon beam energy
a
Mean dose (range) (Gy)
Dose grouping
b Cancer site Tangential breast fields
Tangential breast fields+
supraclavicular
High Oesophagus 1.1 5.6 (1.2–19.0)
Pleura n.a. n.a.
Lung (ipsilateral/contralateral) 5.7 (0.8–42)/0.9 10.0 (1.4–42)/1.1
Bone (0.03–50.0) (0.5–50.0)
Connective tissue (heart) 2.2 (0.8–5.5) 2.5 (1.0–6.0)
Medium Stomach 0.5 0.5
Liver 0.9 (0.3–3.0) 0.9 (0.3–3.0)
Gall bladder 0.8 0.9
Larynx 0.6 3.2 (2.0–5.0)
Thyroid 0.9 10.0 (6.0–25.0)
CNS (0.2–1.0) (0.3–19.0)
Low Oral cavity (0.2–0.4) (0.5–1.3)
Salivary gland 0.3 0.8
Colon 0.2 0.2
Rectum 0.06 0.07
Pancreas 0.48 0.5
Melanoma of the skin n.a. n.a.
Cervix uteri 0.06 0.1
Ovary 0.07 0.1
Endometrial 0.06 0.1
Other female genital 0.05 0.1
Bladder 0.05 0.1
Kidney 0.45 0.5
Renal/other urinary tract 0.45 0.5
Brain 0.1 0.2
Other sites o0.5 o0.5
Contralateral breast 1.0 (0.6–4.0) 1.2 (0.8–4.4)
Abbreviations: CNS¼central nervous system; n.a.¼not available. Ipsilateral and contralateral lung, respectively.
aAddition of an electron beam boost field was also
considered, but this did not change the dose category for the second cancer as the additional scatter doses were minimal.
bDose grouping used in the paper: high (41Gy),
medium (0.5–0.99Gy) and low (o0.5Gy) are on the basis of tangential breast fields.
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